Association of arterial stiffness with coronary flow reserve in revascularized coronary artery disease patients

Table 1 Clinical, biochemical and vascular markers of the study population

Variables	Values (n = 70)
Clinical
Age (yr)	60.2 ± 9.8
Gender (males), n (%)	59 (84.3)
Hypertension, n (%)	38 (54.2)
DM, n (%)	23 (32.8)
Dyslipidemia, n (%)	57 (81.4)
Smoking, n (%)	43 (61.5)
FH of CAD, n (%)	25 (35.7)
SBP (mmHg)	128 ± 18
DBP (mmHg)	77 ± 10
Medications
ASA n (%)	70 (100)
Nitrates n (%)	38 (54.3)
ACEIs/ARBS n (%)	59 (84.2)
CCBs n (%)	12 (17.1)
Statins n (%)	65 (92.8)
β-blockers n (%)	60 (85.5)
Biochemical
Chol (mg/dL)	198.8 ± 40.8
TG (mg/dL)	148.2 ± 79.9
HDL (mg/dL)	40.9 ± 11.4
LDL (mg/dL)	134.5 ± 35.9
Glu (mg/dL)	106.5 ± 32.5
CRP (mg/L)	2.44 ± 1.66
Lp-PLA2 (ng/mL)	231.9 ± 90.9
Vascular markers
CFR	2.65 ± 0.94
RHI-PAT	1.37 ± 0.43
PWVc (m/s)	10.32 ± 2.39
AIx (%)	35.8 ± 15.4
SAI (%)	50.6 ± 8.7
DAI (%)	49.4 ± 8.7
DRA	45.4 ± 12.6
RT (ms)	115.1 ± 22.5
SBPc (mm Hg)	133.2 ± 19.6
DBPc (mmHg)	83.3 ± 12.4

FH: Family history; CAD: Coronary artery disease; DM: Diabetes mellitus; SBP: Systolic blood pressure; DBP: Diastolic blood pressure; ASA: Acetylsalycilic acid; ACEIs: Angiotensin converting enzyme inhibitors; ARBs: Angiotensin receptors blockers; CCBs: Calcium channel blockers; Chol: Total cholesterol; TG: Triglycerides; LDL: Low density; HDL: High density lipoprotein; FPG: Fasting plasma glucose; CRP: C-reactive protein; Lp-PLA₂: Lipoprotein-phospholipase A₂ patients with multivessel coronary artery disease before revascularisation; CFR: Coronary flow reserve; PWVc: Pulse wave velocity as measured with complior apparatus; AIx: Augmentation index; SAI: Systolic area index; DAI: Diastolic area index; DRA: Diastolic reflection area; RT: Return time; SBPc: Central systolic blood pressure.